Binnopharm Group launches an antihistamine gel
10.06.2024
The pharmaceutical company Binnopharm Group has launched the new antihistamine product Dermastil AKOS 0.1% Topical Gel in three sizes: 30 g, 50 g, and 100 g tubes. The product will expand the lineup of currently available generics in the dermatological segment, which is growing rapidly.
Dermastil AKOS Gel is already commercially available. The gel is produced at the Sintez manufacturing facility (included in Binnopharm Group). The product has an anti-allergic and anti-pruritic effect, and exhibits strong local anesthetic activity. The product is intended for the treatment of adults and children over one month of age.
The company’s portfolio includes more than ten products of various pharmaceutical forms to treat allergy. Dermastil AKOS Gel will expand the lineup of topical medicinal products.
Sergey Komarov, Director for Planning and Business Analysis of Binnopharm Group: «We always observe the needs of the market for certain products. Demand for antihistamine medicinal products is stable, therefore the introduction of Dermastil AKOS Gel into the market will contribute to meeting patients’ need for quality topical product. The market volume currently amounts to 1.4 billion rubles, with a growth of 34% (MAT`3 2024). Binnopharm Group plans to take leading positions in this segment».
Dermastil AKOS Gel is already commercially available. The gel is produced at the Sintez manufacturing facility (included in Binnopharm Group). The product has an anti-allergic and anti-pruritic effect, and exhibits strong local anesthetic activity. The product is intended for the treatment of adults and children over one month of age.
The company’s portfolio includes more than ten products of various pharmaceutical forms to treat allergy. Dermastil AKOS Gel will expand the lineup of topical medicinal products.
Sergey Komarov, Director for Planning and Business Analysis of Binnopharm Group: «We always observe the needs of the market for certain products. Demand for antihistamine medicinal products is stable, therefore the introduction of Dermastil AKOS Gel into the market will contribute to meeting patients’ need for quality topical product. The market volume currently amounts to 1.4 billion rubles, with a growth of 34% (MAT`3 2024). Binnopharm Group plans to take leading positions in this segment».
